IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea
CyPath® Lung sales up 276% year-over-year bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2025. Key Highlights Generated revenue of $1.9 million in the first quarter of 2025. CyPath® Lung sales up 276% year-over-year in the first quarter of 2025. Reported strong results from the Texas beta launch of CyPath® Lung, with first-quarter test sales building on the momentum of more than 600 tests delivered in 2024. Announced strategic actions expected to reduce annual c
Dr. Gordon Downie shares case-based evidence demonstrating how CyPath® Lung improves diagnostic confidence and guides care in high-risk patients bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced the release of a white paper authored by Dr. Gordon Downie, MD, PhD, Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center. The paper, titled "CyPath® Lung in Practice: Cases 1-4," details real-world clinical cases in which CyPath® Lung, a noninvasive sputum-based test, significantly influenced clinical decision-m
JERSEY CITY, N.J., May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company. The offering consist
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company. The offering consisted of 10,156,250 shares (the "Shares") of our Common Stock (or pre-funded warrants), together with warrants to purchase up to 15,234,375 shares of Common Stock, (the "May 2025 Warrants"). The combined public offering price for each share of common stock (or pr
JERSEY CITY, N.J., May 6, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ:BIAF) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 10,156,250 shares (the "Shar
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 10,156,250 shares (the "Shares") of our Common Stock (or pre-funded warrants), together with warrants to initially purchase up to 15,234,375 shares of Common Stock, (the "May 2025 Warrants"). The combined public offering price for each share of common stock (or pre-funded warra
Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection. bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency measures for its flagship product, CyPath® Lung, the Company's noninvasive test for detection of lung cancer. These improvements are projected to decrease the time required to acquire sample data for analysis by nearly 50% and reduce the cost of sample processing by approximately 60%. The recent enhancements streaml
Increased Demand, Expanded Insurance Coverage Drive Record Growth bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024. 2024 Highlights Record Revenue: Revenue grew approximately 270% to $9.4 million in 2024, a significant increase from $2.5 million in 2023. Increased Demand: CyPath® Lung orders grew by approximately 1,400% over full-year 2023, reflecting increasing physician adoption. CyPath® Lung Reimbursed by Medicare and Private Insurance: The unique CPT code for Cy
Case Demonstrates Benefit of Integrating CyPath® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) today released a case study in which a positive CyPath® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent successful surgery in 2023. "The CyPath® Lung test provided real-time information that was pivotal in identifying a second primary lung cancer, which might have been missed with standard follow-up protocols," bioAffinity Technologies President and CEO Maria Zannes sa
PRER14A - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
10-Q - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
424B4 - bioAffinity Technologies, Inc. (0001712762) (Filer)
EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)
S-1/A - bioAffinity Technologies, Inc. (0001712762) (Filer)
S-1 - bioAffinity Technologies, Inc. (0001712762) (Filer)
10-K/A - bioAffinity Technologies, Inc. (0001712762) (Filer)
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloombe
Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity's Board of Directors Conference Call at 4:30 p.m. Eastern time Today bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. The laboratory assets are being acquire
Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions. Event: bioAffinity Technologies Fourth Quarter 2022 Financial Results Date: Monday, April 3, 2023 Time: 9:00 a.m. EDT Toll Free: 1-877-270-2148 International: 1-412-902-6510 Webcast: Webcast link A replay o
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath® Lung, the Company's noninvasive test to detect early-stage lung cancer. Reported accelerating growth of 350% in CyPath® Lung tests ordered and processed in Q1 2024 as
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets. "Dr. Platt's impressive track record in transforming research organizations into successful commercial entities, her commitment to operational excellence and innovation, and her extensive experience in expanding product market share in the diagnostics market make her a valuable asset to our team as we move forward
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231115775728/en/A partnership to improve lung cancer screening. (Graphic: Business Wire) "The Power of Three" campaign emphasizes the importance of joining forces in the fight against lung cancer by supporting local programs like the Quality Improvement Program to Increase Lu
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America's therapeutic solutions division. Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. "We are delighted
Company enlists Havas Health & You, Trinity Life Sciences to help build CyPath® Lung brand bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies' Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector. CyPath® Lung is a non-invasive test that detects early-stage lung cancer by automated flow cytometry and machine learnin